Fulgent Genetics (FLGT) investor relations material

Executive summary

• Q2 2026 revenue reached $85.4 million, up 4% year-over-year and 20% sequentially, driven by acquisitions and growth in anatomic pathology and BioPharma services, while precision diagnostics declined due to a major customer internalizing testing.

• Therapeutic pipeline advanced with FID-007 showing promising Phase 2 results and Phase 3 preparations underway; FID-022 progressing through Phase 1.

• AI and digital pathology solutions expanded, including a novel mast cell quantification algorithm and enhanced whole genome sequencing capabilities.

• Net loss attributable to shareholders was $29.5 million ($1.05 per share) GAAP; non-GAAP net loss was $16.2 million ($0.58 per share).

• Revenue cycle management and billing system transition caused billing delays, reduced collection rates, and impacted recognized revenue.

Financial highlights

• GAAP gross margin was 30.1% for Q2 2026, down from 42% prior year; non-GAAP gross margin was 31.3% (down from 44.2%).

• GAAP operating loss was $36.1 million; non-GAAP operating loss was $22.4 million (operating margin -26.2%).

• Adjusted EBITDA loss was $17.1 million for Q2 2026.

• Ended Q2 with $551.5 million in cash, cash equivalents, restricted cash, and marketable securities.

• Repurchased 4.1 million shares for $63.9 million in H1 2026; $75.8 million remains authorized for future repurchases.

Outlook and guidance

• Full-year 2026 revenue guidance revised to $330–$340 million, reflecting lower collection rates and customer transition.

• Non-GAAP EPS loss forecasted at $2.22–$2.35 per share for 2026.

• Projected year-end cash position of $610 million, assuming receipt of $106.1 million in tax refunds.

• R&D expenses expected to rise as clinical trials for FID-007 and FID-022 progress.

• Focus on expanding customer base, integrating acquisitions, and resolving billing system issues to improve collections and margins.